Challenges and strategies for the delivery of biologics to the cornea

Biologics, like peptides, proteins and nucleic acids, have proven to be promising drugs for the treatment of numerous diseases. However, besides off label use monoclonal antibody bevacizumab corneal neovascularization, date no other biologics diseases reached market. Indeed, delivering in eye remains a challenge, especially at level cornea. While it appears rather accessible tissue administration drugs, cornea fact presents several anatomical barriers delivery. In addition, also intracellular delivery need overcome achieve therapeutic outcome with biologics. This review outlines efforts that been reported successfully deliver into Biochemical physical methods achieving are discussed, critical view on their efficacy overcoming barriers.